nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2J2—Cholecalciferol—osteoporosis	0.393	0.527	CbGbCtD
Levomilnacipran—CYP2C8—Raloxifene—osteoporosis	0.0356	0.0477	CbGbCtD
Levomilnacipran—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0344	0.046	CbGbCtD
Levomilnacipran—CYP2C8—Cholecalciferol—osteoporosis	0.0275	0.0368	CbGbCtD
Levomilnacipran—ABCB1—Ethinyl Estradiol—osteoporosis	0.0233	0.0312	CbGbCtD
Levomilnacipran—CYP2C19—Cholecalciferol—osteoporosis	0.0231	0.0309	CbGbCtD
Levomilnacipran—CYP2C8—Estradiol—osteoporosis	0.0222	0.0297	CbGbCtD
Levomilnacipran—CYP3A4—Estropipate—osteoporosis	0.0216	0.029	CbGbCtD
Levomilnacipran—CYP3A4—Calcitriol—osteoporosis	0.0216	0.029	CbGbCtD
Levomilnacipran—CYP2C19—Estradiol—osteoporosis	0.0186	0.0249	CbGbCtD
Levomilnacipran—CYP2D6—Cholecalciferol—osteoporosis	0.0175	0.0235	CbGbCtD
Levomilnacipran—CYP3A4—Ergocalciferol—osteoporosis	0.0173	0.0232	CbGbCtD
Levomilnacipran—ABCB1—Conjugated Estrogens—osteoporosis	0.0171	0.0229	CbGbCtD
Levomilnacipran—ABCB1—Estradiol—osteoporosis	0.015	0.0201	CbGbCtD
Levomilnacipran—CYP3A4—Raloxifene—osteoporosis	0.0144	0.0193	CbGbCtD
Levomilnacipran—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0139	0.0187	CbGbCtD
Levomilnacipran—CYP3A4—Cholecalciferol—osteoporosis	0.0111	0.0149	CbGbCtD
Levomilnacipran—CYP3A4—Conjugated Estrogens—osteoporosis	0.0102	0.0137	CbGbCtD
Levomilnacipran—CYP3A4—Estradiol—osteoporosis	0.00899	0.012	CbGbCtD
Levomilnacipran—Shock—Pamidronate—osteoporosis	0.000253	0.00112	CcSEcCtD
Levomilnacipran—Loss of consciousness—Zoledronate—osteoporosis	0.000253	0.00112	CcSEcCtD
Levomilnacipran—Hypersensitivity—Estropipate—osteoporosis	0.000252	0.00112	CcSEcCtD
Levomilnacipran—Nervous system disorder—Pamidronate—osteoporosis	0.000252	0.00112	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Pamidronate—osteoporosis	0.000252	0.00112	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Estradiol—osteoporosis	0.000252	0.00112	CcSEcCtD
Levomilnacipran—Vomiting—Etidronic acid—osteoporosis	0.000251	0.00111	CcSEcCtD
Levomilnacipran—Oedema peripheral—Estradiol—osteoporosis	0.000251	0.00111	CcSEcCtD
Levomilnacipran—Tachycardia—Pamidronate—osteoporosis	0.000251	0.00111	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Estradiol—osteoporosis	0.00025	0.00111	CcSEcCtD
Levomilnacipran—Urethral disorder—Estradiol—osteoporosis	0.00025	0.00111	CcSEcCtD
Levomilnacipran—Rash—Etidronic acid—osteoporosis	0.000249	0.00111	CcSEcCtD
Levomilnacipran—Convulsion—Zoledronate—osteoporosis	0.000249	0.00111	CcSEcCtD
Levomilnacipran—Dermatitis—Etidronic acid—osteoporosis	0.000249	0.0011	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Pamidronate—osteoporosis	0.000249	0.0011	CcSEcCtD
Levomilnacipran—Syncope—Conjugated Estrogens—osteoporosis	0.000248	0.0011	CcSEcCtD
Levomilnacipran—Hypertension—Zoledronate—osteoporosis	0.000248	0.0011	CcSEcCtD
Levomilnacipran—Hypersensitivity—Alendronate—osteoporosis	0.000248	0.0011	CcSEcCtD
Levomilnacipran—Headache—Etidronic acid—osteoporosis	0.000248	0.0011	CcSEcCtD
Levomilnacipran—Asthenia—Estropipate—osteoporosis	0.000246	0.00109	CcSEcCtD
Levomilnacipran—Anorexia—Pamidronate—osteoporosis	0.000245	0.00109	CcSEcCtD
Levomilnacipran—Chest pain—Zoledronate—osteoporosis	0.000245	0.00109	CcSEcCtD
Levomilnacipran—Palpitations—Conjugated Estrogens—osteoporosis	0.000245	0.00109	CcSEcCtD
Levomilnacipran—Insomnia—Risedronate—osteoporosis	0.000245	0.00108	CcSEcCtD
Levomilnacipran—Anxiety—Zoledronate—osteoporosis	0.000244	0.00108	CcSEcCtD
Levomilnacipran—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000243	0.00108	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000243	0.00108	CcSEcCtD
Levomilnacipran—Paraesthesia—Risedronate—osteoporosis	0.000243	0.00108	CcSEcCtD
Levomilnacipran—Pruritus—Estropipate—osteoporosis	0.000242	0.00107	CcSEcCtD
Levomilnacipran—Asthenia—Alendronate—osteoporosis	0.000242	0.00107	CcSEcCtD
Levomilnacipran—Hypersensitivity—Ibandronate—osteoporosis	0.000242	0.00107	CcSEcCtD
Levomilnacipran—Dyspnoea—Risedronate—osteoporosis	0.000241	0.00107	CcSEcCtD
Levomilnacipran—Erythema multiforme—Estradiol—osteoporosis	0.000241	0.00107	CcSEcCtD
Levomilnacipran—Hypotension—Pamidronate—osteoporosis	0.00024	0.00106	CcSEcCtD
Levomilnacipran—Convulsion—Conjugated Estrogens—osteoporosis	0.00024	0.00106	CcSEcCtD
Levomilnacipran—Dry mouth—Zoledronate—osteoporosis	0.00024	0.00106	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000239	0.00106	CcSEcCtD
Levomilnacipran—Fatigue—Ethinyl Estradiol—osteoporosis	0.000239	0.00106	CcSEcCtD
Levomilnacipran—Pruritus—Alendronate—osteoporosis	0.000238	0.00106	CcSEcCtD
Levomilnacipran—Dyspepsia—Risedronate—osteoporosis	0.000238	0.00106	CcSEcCtD
Levomilnacipran—Eye disorder—Estradiol—osteoporosis	0.000238	0.00106	CcSEcCtD
Levomilnacipran—Constipation—Ethinyl Estradiol—osteoporosis	0.000237	0.00105	CcSEcCtD
Levomilnacipran—Hypersensitivity—Calcitriol—osteoporosis	0.000237	0.00105	CcSEcCtD
Levomilnacipran—Cardiac disorder—Estradiol—osteoporosis	0.000236	0.00105	CcSEcCtD
Levomilnacipran—Flushing—Estradiol—osteoporosis	0.000236	0.00105	CcSEcCtD
Levomilnacipran—Chest pain—Conjugated Estrogens—osteoporosis	0.000236	0.00105	CcSEcCtD
Levomilnacipran—Asthenia—Ibandronate—osteoporosis	0.000235	0.00104	CcSEcCtD
Levomilnacipran—Anxiety—Conjugated Estrogens—osteoporosis	0.000235	0.00104	CcSEcCtD
Levomilnacipran—Nausea—Etidronic acid—osteoporosis	0.000235	0.00104	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000234	0.00104	CcSEcCtD
Levomilnacipran—Diarrhoea—Estropipate—osteoporosis	0.000234	0.00104	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Risedronate—osteoporosis	0.000233	0.00103	CcSEcCtD
Levomilnacipran—Infection—Zoledronate—osteoporosis	0.000233	0.00103	CcSEcCtD
Levomilnacipran—Fatigue—Risedronate—osteoporosis	0.000233	0.00103	CcSEcCtD
Levomilnacipran—Insomnia—Pamidronate—osteoporosis	0.000233	0.00103	CcSEcCtD
Levomilnacipran—Pruritus—Ibandronate—osteoporosis	0.000232	0.00103	CcSEcCtD
Levomilnacipran—Constipation—Risedronate—osteoporosis	0.000231	0.00103	CcSEcCtD
Levomilnacipran—Angiopathy—Estradiol—osteoporosis	0.000231	0.00102	CcSEcCtD
Levomilnacipran—Shock—Zoledronate—osteoporosis	0.000231	0.00102	CcSEcCtD
Levomilnacipran—Paraesthesia—Pamidronate—osteoporosis	0.000231	0.00102	CcSEcCtD
Levomilnacipran—Diarrhoea—Alendronate—osteoporosis	0.000231	0.00102	CcSEcCtD
Levomilnacipran—Asthenia—Calcitriol—osteoporosis	0.00023	0.00102	CcSEcCtD
Levomilnacipran—Nervous system disorder—Zoledronate—osteoporosis	0.00023	0.00102	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Zoledronate—osteoporosis	0.00023	0.00102	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Estradiol—osteoporosis	0.00023	0.00102	CcSEcCtD
Levomilnacipran—Dyspnoea—Pamidronate—osteoporosis	0.000229	0.00102	CcSEcCtD
Levomilnacipran—Tachycardia—Zoledronate—osteoporosis	0.000229	0.00102	CcSEcCtD
Levomilnacipran—Chills—Estradiol—osteoporosis	0.000229	0.00101	CcSEcCtD
Levomilnacipran—Somnolence—Pamidronate—osteoporosis	0.000229	0.00101	CcSEcCtD
Levomilnacipran—Skin disorder—Zoledronate—osteoporosis	0.000228	0.00101	CcSEcCtD
Levomilnacipran—Pruritus—Calcitriol—osteoporosis	0.000227	0.00101	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Zoledronate—osteoporosis	0.000227	0.00101	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000227	0.00101	CcSEcCtD
Levomilnacipran—Diarrhoea—Raloxifene—osteoporosis	0.000227	0.00101	CcSEcCtD
Levomilnacipran—Dyspepsia—Pamidronate—osteoporosis	0.000226	0.001	CcSEcCtD
Levomilnacipran—Dizziness—Estropipate—osteoporosis	0.000226	0.001	CcSEcCtD
Levomilnacipran—Infection—Conjugated Estrogens—osteoporosis	0.000225	0.000996	CcSEcCtD
Levomilnacipran—Diarrhoea—Ibandronate—osteoporosis	0.000225	0.000995	CcSEcCtD
Levomilnacipran—Anorexia—Zoledronate—osteoporosis	0.000224	0.000992	CcSEcCtD
Levomilnacipran—Decreased appetite—Pamidronate—osteoporosis	0.000223	0.000991	CcSEcCtD
Levomilnacipran—Mental disorder—Estradiol—osteoporosis	0.000223	0.000989	CcSEcCtD
Levomilnacipran—Dizziness—Alendronate—osteoporosis	0.000223	0.000988	CcSEcCtD
Levomilnacipran—Shock—Conjugated Estrogens—osteoporosis	0.000222	0.000986	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000222	0.000984	CcSEcCtD
Levomilnacipran—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000222	0.000983	CcSEcCtD
Levomilnacipran—Malnutrition—Estradiol—osteoporosis	0.000222	0.000983	CcSEcCtD
Levomilnacipran—Fatigue—Pamidronate—osteoporosis	0.000222	0.000982	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Risedronate—osteoporosis	0.000221	0.00098	CcSEcCtD
Levomilnacipran—Tachycardia—Conjugated Estrogens—osteoporosis	0.000221	0.000978	CcSEcCtD
Levomilnacipran—Urticaria—Ethinyl Estradiol—osteoporosis	0.00022	0.000977	CcSEcCtD
Levomilnacipran—Constipation—Pamidronate—osteoporosis	0.00022	0.000975	CcSEcCtD
Levomilnacipran—Diarrhoea—Calcitriol—osteoporosis	0.00022	0.000974	CcSEcCtD
Levomilnacipran—Skin disorder—Conjugated Estrogens—osteoporosis	0.00022	0.000974	CcSEcCtD
Levomilnacipran—Hypotension—Zoledronate—osteoporosis	0.000219	0.000973	CcSEcCtD
Levomilnacipran—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000219	0.000972	CcSEcCtD
Levomilnacipran—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000219	0.000972	CcSEcCtD
Levomilnacipran—Dizziness—Raloxifene—osteoporosis	0.000219	0.000972	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000219	0.000969	CcSEcCtD
Levomilnacipran—Flatulence—Estradiol—osteoporosis	0.000218	0.000969	CcSEcCtD
Levomilnacipran—Tension—Estradiol—osteoporosis	0.000218	0.000965	CcSEcCtD
Levomilnacipran—Vomiting—Estropipate—osteoporosis	0.000218	0.000964	CcSEcCtD
Levomilnacipran—Dysgeusia—Estradiol—osteoporosis	0.000217	0.000963	CcSEcCtD
Levomilnacipran—Dizziness—Ibandronate—osteoporosis	0.000217	0.000962	CcSEcCtD
Levomilnacipran—Rash—Estropipate—osteoporosis	0.000216	0.000956	CcSEcCtD
Levomilnacipran—Dermatitis—Estropipate—osteoporosis	0.000216	0.000956	CcSEcCtD
Levomilnacipran—Anorexia—Conjugated Estrogens—osteoporosis	0.000216	0.000955	CcSEcCtD
Levomilnacipran—Urticaria—Risedronate—osteoporosis	0.000215	0.000952	CcSEcCtD
Levomilnacipran—Headache—Estropipate—osteoporosis	0.000214	0.00095	CcSEcCtD
Levomilnacipran—Vomiting—Alendronate—osteoporosis	0.000214	0.00095	CcSEcCtD
Levomilnacipran—Body temperature increased—Risedronate—osteoporosis	0.000214	0.000948	CcSEcCtD
Levomilnacipran—Abdominal pain—Risedronate—osteoporosis	0.000214	0.000948	CcSEcCtD
Levomilnacipran—Rash—Alendronate—osteoporosis	0.000213	0.000942	CcSEcCtD
Levomilnacipran—Insomnia—Zoledronate—osteoporosis	0.000212	0.000941	CcSEcCtD
Levomilnacipran—Dermatitis—Alendronate—osteoporosis	0.000212	0.000941	CcSEcCtD
Levomilnacipran—Hypotension—Conjugated Estrogens—osteoporosis	0.000211	0.000937	CcSEcCtD
Levomilnacipran—Headache—Alendronate—osteoporosis	0.000211	0.000936	CcSEcCtD
Levomilnacipran—Paraesthesia—Zoledronate—osteoporosis	0.000211	0.000935	CcSEcCtD
Levomilnacipran—Vomiting—Raloxifene—osteoporosis	0.000211	0.000934	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Pamidronate—osteoporosis	0.00021	0.000932	CcSEcCtD
Levomilnacipran—Dyspnoea—Zoledronate—osteoporosis	0.000209	0.000928	CcSEcCtD
Levomilnacipran—Rash—Raloxifene—osteoporosis	0.000209	0.000926	CcSEcCtD
Levomilnacipran—Dermatitis—Raloxifene—osteoporosis	0.000209	0.000926	CcSEcCtD
Levomilnacipran—Somnolence—Zoledronate—osteoporosis	0.000209	0.000925	CcSEcCtD
Levomilnacipran—Vomiting—Ibandronate—osteoporosis	0.000209	0.000925	CcSEcCtD
Levomilnacipran—Tremor—Estradiol—osteoporosis	0.000208	0.000921	CcSEcCtD
Levomilnacipran—Headache—Raloxifene—osteoporosis	0.000208	0.00092	CcSEcCtD
Levomilnacipran—Rash—Ibandronate—osteoporosis	0.000207	0.000917	CcSEcCtD
Levomilnacipran—Dermatitis—Ibandronate—osteoporosis	0.000207	0.000916	CcSEcCtD
Levomilnacipran—Dyspepsia—Zoledronate—osteoporosis	0.000207	0.000916	CcSEcCtD
Levomilnacipran—Headache—Ibandronate—osteoporosis	0.000206	0.000911	CcSEcCtD
Levomilnacipran—Insomnia—Conjugated Estrogens—osteoporosis	0.000204	0.000907	CcSEcCtD
Levomilnacipran—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000204	0.000906	CcSEcCtD
Levomilnacipran—Vomiting—Calcitriol—osteoporosis	0.000204	0.000905	CcSEcCtD
Levomilnacipran—Decreased appetite—Zoledronate—osteoporosis	0.000204	0.000905	CcSEcCtD
Levomilnacipran—Agitation—Estradiol—osteoporosis	0.000204	0.000903	CcSEcCtD
Levomilnacipran—Nausea—Estropipate—osteoporosis	0.000203	0.000901	CcSEcCtD
Levomilnacipran—Abdominal pain—Pamidronate—osteoporosis	0.000203	0.000901	CcSEcCtD
Levomilnacipran—Body temperature increased—Pamidronate—osteoporosis	0.000203	0.000901	CcSEcCtD
Levomilnacipran—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000203	0.0009	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000203	0.000899	CcSEcCtD
Levomilnacipran—Rash—Calcitriol—osteoporosis	0.000203	0.000898	CcSEcCtD
Levomilnacipran—Fatigue—Zoledronate—osteoporosis	0.000202	0.000897	CcSEcCtD
Levomilnacipran—Dermatitis—Calcitriol—osteoporosis	0.000202	0.000897	CcSEcCtD
Levomilnacipran—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000202	0.000894	CcSEcCtD
Levomilnacipran—Headache—Calcitriol—osteoporosis	0.000201	0.000892	CcSEcCtD
Levomilnacipran—Somnolence—Conjugated Estrogens—osteoporosis	0.000201	0.000891	CcSEcCtD
Levomilnacipran—Constipation—Zoledronate—osteoporosis	0.000201	0.00089	CcSEcCtD
Levomilnacipran—Nausea—Alendronate—osteoporosis	0.0002	0.000887	CcSEcCtD
Levomilnacipran—Hypersensitivity—Risedronate—osteoporosis	0.000199	0.000883	CcSEcCtD
Levomilnacipran—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000199	0.000882	CcSEcCtD
Levomilnacipran—Asthenia—Ethinyl Estradiol—osteoporosis	0.000199	0.000882	CcSEcCtD
Levomilnacipran—Syncope—Estradiol—osteoporosis	0.000199	0.000881	CcSEcCtD
Levomilnacipran—Nausea—Raloxifene—osteoporosis	0.000197	0.000873	CcSEcCtD
Levomilnacipran—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000197	0.000871	CcSEcCtD
Levomilnacipran—Pruritus—Ethinyl Estradiol—osteoporosis	0.000196	0.00087	CcSEcCtD
Levomilnacipran—Palpitations—Estradiol—osteoporosis	0.000196	0.000869	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000195	0.000865	CcSEcCtD
Levomilnacipran—Fatigue—Conjugated Estrogens—osteoporosis	0.000195	0.000864	CcSEcCtD
Levomilnacipran—Nausea—Ibandronate—osteoporosis	0.000195	0.000864	CcSEcCtD
Levomilnacipran—Loss of consciousness—Estradiol—osteoporosis	0.000195	0.000864	CcSEcCtD
Levomilnacipran—Asthenia—Risedronate—osteoporosis	0.000194	0.00086	CcSEcCtD
Levomilnacipran—Constipation—Conjugated Estrogens—osteoporosis	0.000193	0.000857	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Zoledronate—osteoporosis	0.000192	0.000851	CcSEcCtD
Levomilnacipran—Hypertension—Estradiol—osteoporosis	0.000191	0.000849	CcSEcCtD
Levomilnacipran—Pruritus—Risedronate—osteoporosis	0.000191	0.000848	CcSEcCtD
Levomilnacipran—Nausea—Calcitriol—osteoporosis	0.000191	0.000846	CcSEcCtD
Levomilnacipran—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00019	0.000841	CcSEcCtD
Levomilnacipran—Hypersensitivity—Pamidronate—osteoporosis	0.000189	0.00084	CcSEcCtD
Levomilnacipran—Chest pain—Estradiol—osteoporosis	0.000189	0.000837	CcSEcCtD
Levomilnacipran—Anxiety—Estradiol—osteoporosis	0.000188	0.000834	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000187	0.000831	CcSEcCtD
Levomilnacipran—Urticaria—Zoledronate—osteoporosis	0.000187	0.000827	CcSEcCtD
Levomilnacipran—Abdominal pain—Zoledronate—osteoporosis	0.000186	0.000823	CcSEcCtD
Levomilnacipran—Body temperature increased—Zoledronate—osteoporosis	0.000186	0.000823	CcSEcCtD
Levomilnacipran—Diarrhoea—Risedronate—osteoporosis	0.000185	0.00082	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000185	0.00082	CcSEcCtD
Levomilnacipran—Dry mouth—Estradiol—osteoporosis	0.000185	0.000818	CcSEcCtD
Levomilnacipran—Asthenia—Pamidronate—osteoporosis	0.000184	0.000818	CcSEcCtD
Levomilnacipran—Dizziness—Ethinyl Estradiol—osteoporosis	0.000183	0.000813	CcSEcCtD
Levomilnacipran—Pruritus—Pamidronate—osteoporosis	0.000182	0.000806	CcSEcCtD
Levomilnacipran—Infection—Estradiol—osteoporosis	0.00018	0.000797	CcSEcCtD
Levomilnacipran—Urticaria—Conjugated Estrogens—osteoporosis	0.00018	0.000796	CcSEcCtD
Levomilnacipran—Dizziness—Risedronate—osteoporosis	0.000179	0.000793	CcSEcCtD
Levomilnacipran—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000179	0.000792	CcSEcCtD
Levomilnacipran—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000179	0.000792	CcSEcCtD
Levomilnacipran—Shock—Estradiol—osteoporosis	0.000178	0.000789	CcSEcCtD
Levomilnacipran—Nervous system disorder—Estradiol—osteoporosis	0.000177	0.000787	CcSEcCtD
Levomilnacipran—Tachycardia—Estradiol—osteoporosis	0.000177	0.000783	CcSEcCtD
Levomilnacipran—Vomiting—Ethinyl Estradiol—osteoporosis	0.000176	0.000782	CcSEcCtD
Levomilnacipran—Diarrhoea—Pamidronate—osteoporosis	0.000176	0.00078	CcSEcCtD
Levomilnacipran—Skin disorder—Estradiol—osteoporosis	0.000176	0.000779	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Estradiol—osteoporosis	0.000175	0.000775	CcSEcCtD
Levomilnacipran—Rash—Ethinyl Estradiol—osteoporosis	0.000175	0.000775	CcSEcCtD
Levomilnacipran—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000175	0.000775	CcSEcCtD
Levomilnacipran—Headache—Ethinyl Estradiol—osteoporosis	0.000174	0.00077	CcSEcCtD
Levomilnacipran—Hypersensitivity—Zoledronate—osteoporosis	0.000173	0.000767	CcSEcCtD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000172	0.00626	CbGpPWpGaD
Levomilnacipran—Vomiting—Risedronate—osteoporosis	0.000172	0.000762	CcSEcCtD
Levomilnacipran—Rash—Risedronate—osteoporosis	0.000171	0.000756	CcSEcCtD
Levomilnacipran—Dermatitis—Risedronate—osteoporosis	0.00017	0.000755	CcSEcCtD
Levomilnacipran—Dizziness—Pamidronate—osteoporosis	0.00017	0.000754	CcSEcCtD
Levomilnacipran—Headache—Risedronate—osteoporosis	0.000169	0.000751	CcSEcCtD
Levomilnacipran—Asthenia—Zoledronate—osteoporosis	0.000168	0.000747	CcSEcCtD
Levomilnacipran—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000167	0.000738	CcSEcCtD
Levomilnacipran—Pruritus—Zoledronate—osteoporosis	0.000166	0.000736	CcSEcCtD
Levomilnacipran—Nausea—Ethinyl Estradiol—osteoporosis	0.000165	0.00073	CcSEcCtD
Levomilnacipran—Insomnia—Estradiol—osteoporosis	0.000164	0.000726	CcSEcCtD
Levomilnacipran—Vomiting—Pamidronate—osteoporosis	0.000163	0.000725	CcSEcCtD
Levomilnacipran—Paraesthesia—Estradiol—osteoporosis	0.000162	0.00072	CcSEcCtD
Levomilnacipran—Asthenia—Conjugated Estrogens—osteoporosis	0.000162	0.000719	CcSEcCtD
Levomilnacipran—Rash—Pamidronate—osteoporosis	0.000162	0.000719	CcSEcCtD
Levomilnacipran—Dermatitis—Pamidronate—osteoporosis	0.000162	0.000718	CcSEcCtD
Levomilnacipran—Dyspnoea—Estradiol—osteoporosis	0.000161	0.000715	CcSEcCtD
Levomilnacipran—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000161	0.00585	CbGpPWpGaD
Levomilnacipran—Headache—Pamidronate—osteoporosis	0.000161	0.000714	CcSEcCtD
Levomilnacipran—Somnolence—Estradiol—osteoporosis	0.000161	0.000713	CcSEcCtD
Levomilnacipran—Diarrhoea—Zoledronate—osteoporosis	0.000161	0.000712	CcSEcCtD
Levomilnacipran—Nausea—Risedronate—osteoporosis	0.000161	0.000712	CcSEcCtD
Levomilnacipran—Pruritus—Conjugated Estrogens—osteoporosis	0.00016	0.000709	CcSEcCtD
Levomilnacipran—Dyspepsia—Estradiol—osteoporosis	0.000159	0.000706	CcSEcCtD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000159	0.00576	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000158	0.00574	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Estradiol—osteoporosis	0.000157	0.000697	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Estradiol—osteoporosis	0.000156	0.000693	CcSEcCtD
Levomilnacipran—Fatigue—Estradiol—osteoporosis	0.000156	0.000692	CcSEcCtD
Levomilnacipran—Dizziness—Zoledronate—osteoporosis	0.000155	0.000688	CcSEcCtD
Levomilnacipran—Constipation—Estradiol—osteoporosis	0.000155	0.000686	CcSEcCtD
Levomilnacipran—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000155	0.000686	CcSEcCtD
Levomilnacipran—SLC6A4—Monoamine Transport—TNF—osteoporosis	0.000154	0.0056	CbGpPWpGaD
Levomilnacipran—Nausea—Pamidronate—osteoporosis	0.000153	0.000677	CcSEcCtD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00015	0.00546	CbGpPWpGaD
Levomilnacipran—Dizziness—Conjugated Estrogens—osteoporosis	0.00015	0.000663	CcSEcCtD
Levomilnacipran—Vomiting—Zoledronate—osteoporosis	0.000149	0.000662	CcSEcCtD
Levomilnacipran—Rash—Zoledronate—osteoporosis	0.000148	0.000656	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Estradiol—osteoporosis	0.000148	0.000656	CcSEcCtD
Levomilnacipran—Dermatitis—Zoledronate—osteoporosis	0.000148	0.000656	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000148	0.00537	CbGpPWpGaD
Levomilnacipran—Headache—Zoledronate—osteoporosis	0.000147	0.000652	CcSEcCtD
Levomilnacipran—Vomiting—Conjugated Estrogens—osteoporosis	0.000144	0.000637	CcSEcCtD
Levomilnacipran—Urticaria—Estradiol—osteoporosis	0.000144	0.000637	CcSEcCtD
Levomilnacipran—Body temperature increased—Estradiol—osteoporosis	0.000143	0.000634	CcSEcCtD
Levomilnacipran—Abdominal pain—Estradiol—osteoporosis	0.000143	0.000634	CcSEcCtD
Levomilnacipran—Rash—Conjugated Estrogens—osteoporosis	0.000143	0.000632	CcSEcCtD
Levomilnacipran—Dermatitis—Conjugated Estrogens—osteoporosis	0.000142	0.000631	CcSEcCtD
Levomilnacipran—Headache—Conjugated Estrogens—osteoporosis	0.000142	0.000628	CcSEcCtD
Levomilnacipran—Nausea—Zoledronate—osteoporosis	0.000139	0.000618	CcSEcCtD
Levomilnacipran—Nausea—Conjugated Estrogens—osteoporosis	0.000134	0.000595	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000134	0.00488	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Estradiol—osteoporosis	0.000133	0.000591	CcSEcCtD
Levomilnacipran—SLC6A2—Monoamine Transport—TNF—osteoporosis	0.000132	0.00481	CbGpPWpGaD
Levomilnacipran—Asthenia—Estradiol—osteoporosis	0.00013	0.000576	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—POMC—osteoporosis	0.00013	0.00471	CbGpPWpGaD
Levomilnacipran—Pruritus—Estradiol—osteoporosis	0.000128	0.000568	CcSEcCtD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000128	0.00465	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000126	0.00459	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000126	0.00459	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000125	0.00455	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Estradiol—osteoporosis	0.000124	0.000549	CcSEcCtD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000124	0.00449	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—FDPS—osteoporosis	0.000122	0.00445	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PKM—osteoporosis	0.000122	0.00445	CbGpPWpGaD
Levomilnacipran—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000121	0.00438	CbGpPWpGaD
Levomilnacipran—Dizziness—Estradiol—osteoporosis	0.00012	0.00053	CcSEcCtD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—GPX1—osteoporosis	0.000118	0.00428	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GPD2—osteoporosis	0.000116	0.00422	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PGLS—osteoporosis	0.000116	0.00422	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—AGER—osteoporosis	0.000116	0.00421	CbGpPWpGaD
Levomilnacipran—Vomiting—Estradiol—osteoporosis	0.000115	0.00051	CcSEcCtD
Levomilnacipran—Rash—Estradiol—osteoporosis	0.000114	0.000506	CcSEcCtD
Levomilnacipran—Dermatitis—Estradiol—osteoporosis	0.000114	0.000505	CcSEcCtD
Levomilnacipran—Headache—Estradiol—osteoporosis	0.000113	0.000503	CcSEcCtD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000112	0.00406	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.00011	0.00401	CbGpPWpGaD
Levomilnacipran—Nausea—Estradiol—osteoporosis	0.000107	0.000476	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—ATIC—osteoporosis	0.000106	0.00386	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PNP—osteoporosis	0.000106	0.00386	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—GPX1—osteoporosis	0.000105	0.00382	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000104	0.00377	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000103	0.00373	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP27A1—osteoporosis	0.000103	0.00373	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000101	0.00369	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000101	0.00368	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP27A1—osteoporosis	0.000101	0.00368	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—AGER—osteoporosis	9.97e-05	0.00362	CbGpPWpGaD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	9.25e-05	0.00336	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP27A1—osteoporosis	9.16e-05	0.00333	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	9.06e-05	0.00329	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP27A1—osteoporosis	9.03e-05	0.00328	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CA2—osteoporosis	9.02e-05	0.00328	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—OXCT1—osteoporosis	9.02e-05	0.00328	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MGLL—osteoporosis	8.79e-05	0.00319	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ANXA2—osteoporosis	8.48e-05	0.00308	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	8.42e-05	0.00306	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	8.33e-05	0.00303	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	8.31e-05	0.00302	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	8.31e-05	0.00302	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	8.29e-05	0.00301	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6R—osteoporosis	7.86e-05	0.00286	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—LEP—osteoporosis	7.66e-05	0.00278	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	7.52e-05	0.00273	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—IDH2—osteoporosis	7.48e-05	0.00272	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	7.07e-05	0.00257	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP27A1—osteoporosis	7.03e-05	0.00255	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	6.86e-05	0.00249	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ACP5—osteoporosis	6.84e-05	0.00248	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.75e-05	0.00245	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	6.72e-05	0.00244	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.71e-05	0.00244	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	6.68e-05	0.00243	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	6.63e-05	0.00241	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	6.5e-05	0.00236	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TPI1—osteoporosis	6.36e-05	0.00231	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.18e-05	0.00224	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	6.12e-05	0.00222	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—POMC—osteoporosis	6.1e-05	0.00222	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1B—osteoporosis	5.98e-05	0.00217	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—P4HB—osteoporosis	5.98e-05	0.00217	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GAPDH—osteoporosis	5.87e-05	0.00213	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	5.8e-05	0.00211	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—RAP1A—osteoporosis	5.71e-05	0.00208	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	5.51e-05	0.002	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	5.45e-05	0.00198	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.44e-05	0.00198	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	5.43e-05	0.00197	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP19A1—osteoporosis	5.39e-05	0.00196	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP19A1—osteoporosis	5.32e-05	0.00193	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.06e-05	0.00184	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.01e-05	0.00182	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.98e-05	0.00181	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	4.93e-05	0.00179	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFB1—osteoporosis	4.9e-05	0.00178	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP19A1—osteoporosis	4.81e-05	0.00175	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	4.76e-05	0.00173	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP19A1—osteoporosis	4.74e-05	0.00172	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ENO1—osteoporosis	4.62e-05	0.00168	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PSMA2—osteoporosis	4.55e-05	0.00165	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PSMA5—osteoporosis	4.55e-05	0.00165	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	4.51e-05	0.00164	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	4.45e-05	0.00162	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	4.42e-05	0.00161	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	4.4e-05	0.0016	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	4.36e-05	0.00159	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—osteoporosis	4.34e-05	0.00158	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFB1—osteoporosis	4.21e-05	0.00153	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.04e-05	0.00147	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.94e-05	0.00143	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL1B—osteoporosis	3.9e-05	0.00142	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	3.73e-05	0.00136	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP19A1—osteoporosis	3.69e-05	0.00134	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.52e-05	0.00128	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—osteoporosis	3.5e-05	0.00127	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.35e-05	0.00122	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.27e-05	0.00119	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—POMC—osteoporosis	3.24e-05	0.00118	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.18e-05	0.00116	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PKM—osteoporosis	3.05e-05	0.00111	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—FDPS—osteoporosis	3.05e-05	0.00111	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TGFB1—osteoporosis	3.03e-05	0.0011	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ADCY5—osteoporosis	3.02e-05	0.0011	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GPX1—osteoporosis	3.01e-05	0.00109	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.99e-05	0.00109	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPD2—osteoporosis	2.9e-05	0.00105	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PGLS—osteoporosis	2.9e-05	0.00105	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	2.89e-05	0.00105	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—POMC—osteoporosis	2.89e-05	0.00105	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	2.88e-05	0.00105	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—osteoporosis	2.86e-05	0.00104	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	2.85e-05	0.00104	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—osteoporosis	2.83e-05	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MTHFR—osteoporosis	2.77e-05	0.00101	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PKM—osteoporosis	2.73e-05	0.000991	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FDPS—osteoporosis	2.73e-05	0.000991	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FDPS—osteoporosis	2.66e-05	0.000967	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PKM—osteoporosis	2.66e-05	0.000967	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—POMC—osteoporosis	2.66e-05	0.000966	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PNP—osteoporosis	2.65e-05	0.000963	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ATIC—osteoporosis	2.65e-05	0.000963	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PGLS—osteoporosis	2.59e-05	0.000939	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPD2—osteoporosis	2.59e-05	0.000939	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPD2—osteoporosis	2.52e-05	0.000917	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PGLS—osteoporosis	2.52e-05	0.000917	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PKM—osteoporosis	2.51e-05	0.000911	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FDPS—osteoporosis	2.51e-05	0.000911	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.5e-05	0.000907	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPD2—osteoporosis	2.38e-05	0.000864	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PGLS—osteoporosis	2.38e-05	0.000864	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PNP—osteoporosis	2.36e-05	0.000859	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ATIC—osteoporosis	2.36e-05	0.000859	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ATIC—osteoporosis	2.31e-05	0.000839	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PNP—osteoporosis	2.31e-05	0.000839	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CA2—osteoporosis	2.25e-05	0.000818	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—OXCT1—osteoporosis	2.25e-05	0.000818	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—POMC—osteoporosis	2.22e-05	0.000806	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MGLL—osteoporosis	2.19e-05	0.000798	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PNP—osteoporosis	2.17e-05	0.00079	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ATIC—osteoporosis	2.17e-05	0.00079	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.07e-05	0.000752	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CA2—osteoporosis	2.01e-05	0.000731	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—OXCT1—osteoporosis	2.01e-05	0.000731	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—OXCT1—osteoporosis	1.96e-05	0.000713	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CA2—osteoporosis	1.96e-05	0.000713	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MGLL—osteoporosis	1.96e-05	0.000712	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MGLL—osteoporosis	1.91e-05	0.000695	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—IDH2—osteoporosis	1.87e-05	0.000678	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CA2—osteoporosis	1.85e-05	0.000672	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—OXCT1—osteoporosis	1.85e-05	0.000672	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.85e-05	0.000671	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MGLL—osteoporosis	1.8e-05	0.000655	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP27A1—osteoporosis	1.75e-05	0.000638	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—POMC—osteoporosis	1.74e-05	0.000632	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ACP5—osteoporosis	1.71e-05	0.00062	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.69e-05	0.000612	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—IDH2—osteoporosis	1.67e-05	0.000605	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FDPS—osteoporosis	1.64e-05	0.000596	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PKM—osteoporosis	1.64e-05	0.000596	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—IDH2—osteoporosis	1.63e-05	0.000591	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TPI1—osteoporosis	1.59e-05	0.000577	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP27A1—osteoporosis	1.57e-05	0.000569	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPD2—osteoporosis	1.55e-05	0.000565	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PGLS—osteoporosis	1.55e-05	0.000565	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—IDH2—osteoporosis	1.53e-05	0.000557	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP27A1—osteoporosis	1.53e-05	0.000555	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ACP5—osteoporosis	1.52e-05	0.000554	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.5e-05	0.000547	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.5e-05	0.000545	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.5e-05	0.000544	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—P4HB—osteoporosis	1.49e-05	0.000542	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ACP5—osteoporosis	1.49e-05	0.00054	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GAPDH—osteoporosis	1.46e-05	0.000532	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.44e-05	0.000523	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—RAP1A—osteoporosis	1.43e-05	0.000518	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PNP—osteoporosis	1.42e-05	0.000517	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ATIC—osteoporosis	1.42e-05	0.000517	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TPI1—osteoporosis	1.42e-05	0.000515	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ACP5—osteoporosis	1.4e-05	0.000509	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.4e-05	0.000509	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.4e-05	0.000508	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TPI1—osteoporosis	1.38e-05	0.000502	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—P4HB—osteoporosis	1.33e-05	0.000484	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GAPDH—osteoporosis	1.31e-05	0.000475	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TPI1—osteoporosis	1.3e-05	0.000473	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—P4HB—osteoporosis	1.3e-05	0.000472	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GAPDH—osteoporosis	1.28e-05	0.000464	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—RAP1A—osteoporosis	1.27e-05	0.000463	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.24e-05	0.000452	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—RAP1A—osteoporosis	1.24e-05	0.000452	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—P4HB—osteoporosis	1.22e-05	0.000445	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CA2—osteoporosis	1.21e-05	0.000439	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—OXCT1—osteoporosis	1.21e-05	0.000439	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GAPDH—osteoporosis	1.2e-05	0.000437	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MGLL—osteoporosis	1.18e-05	0.000428	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—RAP1A—osteoporosis	1.17e-05	0.000426	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ENO1—osteoporosis	1.15e-05	0.000419	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PSMA2—osteoporosis	1.14e-05	0.000413	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PSMA5—osteoporosis	1.14e-05	0.000413	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.11e-05	0.000403	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ENO1—osteoporosis	1.03e-05	0.000374	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PSMA2—osteoporosis	1.01e-05	0.000368	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PSMA5—osteoporosis	1.01e-05	0.000368	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ENO1—osteoporosis	1e-05	0.000365	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—IDH2—osteoporosis	1e-05	0.000364	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PSMA2—osteoporosis	9.9e-06	0.00036	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PSMA5—osteoporosis	9.9e-06	0.00036	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ENO1—osteoporosis	9.47e-06	0.000344	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP27A1—osteoporosis	9.42e-06	0.000342	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PSMA5—osteoporosis	9.33e-06	0.000339	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PSMA2—osteoporosis	9.33e-06	0.000339	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP19A1—osteoporosis	9.22e-06	0.000335	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ACP5—osteoporosis	9.16e-06	0.000333	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TPI1—osteoporosis	8.52e-06	0.00031	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP19A1—osteoporosis	8.23e-06	0.000299	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP19A1—osteoporosis	8.03e-06	0.000292	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—P4HB—osteoporosis	8.01e-06	0.000291	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GAPDH—osteoporosis	7.86e-06	0.000286	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—RAP1A—osteoporosis	7.66e-06	0.000278	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP19A1—osteoporosis	7.57e-06	0.000275	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ADCY5—osteoporosis	7.53e-06	0.000274	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPX1—osteoporosis	7.51e-06	0.000273	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—osteoporosis	6.93e-06	0.000252	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ADCY5—osteoporosis	6.72e-06	0.000244	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPX1—osteoporosis	6.7e-06	0.000243	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ADCY5—osteoporosis	6.56e-06	0.000238	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPX1—osteoporosis	6.54e-06	0.000238	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ENO1—osteoporosis	6.19e-06	0.000225	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ADCY5—osteoporosis	6.18e-06	0.000225	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—osteoporosis	6.18e-06	0.000225	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPX1—osteoporosis	6.16e-06	0.000224	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PSMA2—osteoporosis	6.1e-06	0.000222	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PSMA5—osteoporosis	6.1e-06	0.000222	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—osteoporosis	6.03e-06	0.000219	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—osteoporosis	5.69e-06	0.000207	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—POMC—osteoporosis	5.54e-06	0.000201	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP19A1—osteoporosis	4.95e-06	0.00018	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—POMC—osteoporosis	4.94e-06	0.00018	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—POMC—osteoporosis	4.83e-06	0.000175	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—POMC—osteoporosis	4.55e-06	0.000165	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADCY5—osteoporosis	4.04e-06	0.000147	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX1—osteoporosis	4.03e-06	0.000146	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—osteoporosis	3.72e-06	0.000135	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—POMC—osteoporosis	2.97e-06	0.000108	CbGpPWpGaD
